Humacyte (HUMA) director awarded 311,100 stock options at $1.23

Humacyte, Inc. (HUMA) reported a Form 4 for a director showing an indirect grant of stock options held by the director’s spouse.

Rhea-AI Filing Summary

Humacyte, Inc. (HUMA) reported a Form 4 for a director showing an indirect grant of stock options held by the director’s spouse. On 11/16/2025, the spouse acquired 311,100 stock options$1.23 per share

According to the vesting schedule, the first one-third of the options becomes exercisable on February 14, 2026, the next one-third on November 16, 2026, and the final one-third on November 16, 2027. Following this grant, the reporting person indirectly beneficially owns 311,100 derivative securities through the spouse.

Insider Trade Summary

Grant/Award: 311,100 shares

Grant/Award 1 txn

Insider Dougan Brady W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	311,100	$0.00	$0.00

Holdings After Transaction: Stock Options (right to buy) — 311,100 contracts (Indirect, By spouse)

Footnotes (1)

1. F1. The first 1/3 of the option becomes exercisable on February 14, 2026, after which 1/3 of the option will become exercisable on November 16, 2026, and the remaining 1/3 of the option will become exercisable on November 16, 2027.

FAQ

What transaction did Humacyte (HUMA) report in this Form 4?

The filing reports that a director’s spouse acquired 311,100 stock options11/16/2025

What is the exercise price of the Humacyte (HUMA) stock options granted?

The stock options have an exercise price of $1.23 per share

How many Humacyte (HUMA) options does the reporting person beneficially own after the transaction?

After the reported transaction, the director indirectly beneficially owns 311,100 derivative securities

When do the Humacyte (HUMA) stock options begin to vest?

The first one-third of the options becomes exercisable on February 14, 2026November 16, 2026November 16, 2027

When do the reported Humacyte (HUMA) stock options expire?

The stock options reported in this Form 4 expire on 11/16/2035

Is the Humacyte (HUMA) director’s ownership direct or indirect in this filing?

The filing classifies the ownership as indirect (I)“By spouse”

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/17/2025 - 05:49 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dougan Brady W

(Last) (First) (Middle)

2525 EAST NORTH CAROLINA HIGHWAY 54

(Street)

DURHAM NC 27713

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Humacyte, Inc. [ HUMA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$1.23	11/16/2025		A		311,100		(1)	11/16/2035	Common Stock	311,100	$0	311,100	I	By spouse

Explanation of Responses:

1. The first 1/3 of the option becomes exercisable on February 14, 2026, after which 1/3 of the option will become exercisable on November 16, 2026, and the remaining 1/3 of the option will become exercisable on November 16, 2027.

Remarks:

	/s/ Brady W. Dougan by Dale A. Sander as Attorney-in-Fact	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.